Abstract: An information handling system may include at least one processor and a memory. The information handling system may be configured to store a first set of data comprising an operating system in a first location; store a second set of data comprising application data in a second location; expose the first and second sets of data in a combined union mount filesystem; and create a backup of the second set of data, but not the first set of data, by creating a copy of the second location.

Abstract: A modular information handling system may include one or more information handling resources and an enclosure configured to house the one or more information handling resources, the enclosure comprising a topside cover comprising: a fixed portion mechanically fixed to a remaining portion of the enclosure, a movable portion, and a damping hinge configured to rotatably couple the movable portion to the fixed portion about an axis of rotation defined by the damping hinge, wherein the damping hinge is configured to dampen mechanical rotation of the movable portion relative to the fixed portion when the movable portion mechanically moves towards a closed position relative to the fixed portion.

Abstract: A USB conversion charging device for recharging batteries consisting of a USB power input port and, at least, one DC power output port with a power converting circuitry positioned in between the input port and output port; designed to convert USB DC power input voltage and/or current to a different voltage and/or different current DC power output to recharge a battery.

Abstract: Provided herein are compounds, compositions and methods of using the compounds and compositions for the treatment of diseases modulated, as least in part, by AhR. The compounds are represented by formulae Formula (I), (II), (III), (iv): wherein the letters and symbols a, b, c, d, e, f, g, Z, R1b, R2a and R2b have the meanings provided in the specification.

Abstract: Provided are methods for expanding stem cells and/or lineage committed progenitor cells, such as hematopoietic stems cells and/or lineage committed progenitor cells, at least in part, by using compounds that antagonize AhR. The compounds are represented by formulae: wherein the letters and symbols a, b, c, d, e, f, g, Z, R1b, R2a and R2b have the meanings provided in the specification. Also provided are compositions comprising stem cells and/or lineage committed progenitor cells expanded by methods disclosed herein and methods for the treatment of diseases treatable by same.

Abstract: The present disclosure provides methods and systems for managing digital looks. The method may comprise providing access to a digital look. The digital look may comprise a virtual arrangement of one or more fashion articles selected by an algorithm or an individual who is not a consumer. The method may further comprise providing a user interface for a consumer to (i) view and modify the one or more fashion articles in the digital look and (ii) select at least one or more fashion articles to purchase. The user interface may comprise a purchase list corresponding to the one or more fashion articles in the digital look. Modifying the one or more fashion articles in the digital look may comprise rearranging, add, removing, or customizing one or more fashion articles.

Abstract: Provided herein are compounds, compositions and methods of using the compounds and compositions for the treatment of diseases modulated, as least in part, by AhR. The compounds are represented by formulae Formula (I), (II), (III), (iv): wherein the letters and symbols a, b, c, d, e, f, g, Z, R1b, R2a and R2b have the meanings provided in the specification.

Abstract: Methods, compositions and kits for determining the developmental potential of one or more embryos are provided. These methods, compositions and kits find use in identifying embryos in vitro that are most useful in treating infertility in humans.

Abstract: The invention is directed to three-dimensional, engineered, bioprinted biological tissue constructs exhibiting a liver disorder, methods of making the constructs, and use of the constructs in assays, such as drug testing and molecular diagnostic testing, including methods of assessing the ability of a candidate therapeutic agent to reverse, reduce, or prevent a liver disorder, and methods for biomarker discovery.

Abstract: The invention provides methods and uses for delivering progranulin to the central nervous system (CNS) of a mammal. Methods and uses include, for example, administering to a mammal a vector comprising a nucleic acid encoding progranulin, variant, derivative or functional fragment thereof to the mammal's brain ventricle to transduce CNS cells and/or cells that contact the cerebrospinal fluid (CSF) of the mammal such that the cells express the progranulin, variant, derivative or functional fragment thereof.

Abstract: Methods, compositions and kits for determining the developmental potential of one or more embryos are provided. These methods, compositions and kits find use in identifying embryos in vitro that are most useful in treating infertility in humans.

Abstract: Engineered human tissue constructs are provided that are suitable for use in making humanized animals for use in pharmaceutical development. Humanized animals having the constructs implanted in vivo are provided. Methods of making and using the tissue-engineered constructs and humanized animals are also provided.

Abstract: The present invention relates to a method of diagnosing Parkinson's disease in a subject using a novel set of biomarkers. The invention further includes compositions, methods and uses of a novel set of biomarkers to assess the risk of developing Parkinson's disease, to provide pre-symptomatic diagnosis of Parkinson's disease, and to assess prognosis of Parkinson's disease following therapeutic or other intervention.

Abstract: Methods, compositions and kits for determining the developmental potential of one or more embryos are provided. These methods, compositions and kits find use in identifying embryos in vitro that are most useful in treating infertility in humans.

Abstract: Methods, compositions and kits for determining the likelihood of reaching the blastocyst stage for one or more embryos or pluripotent cells are provided. These methods, compositions and kits find use in identifying embryos and oocytes in vitro that are most useful in treating infertility in humans.

Abstract: Methods, compositions and kits for determining the developmental potential of one or more embryos are provided. These methods, compositions and kits find use in identifying embryos in vitro that are most useful in treating infertility in humans.

Abstract: A method for administering object-based multi-level security in a service oriented architecture includes: (a) defining a plurality of multi-level security attributes for each of selected respective life-cycle states of a plurality of life-cycle states of a service object; (b) receiving a request from a requestor for the service object; (c) determining permitted actions for the service object based upon at least one selected multi-level security attribute of the plurality of multi-level security attributes, and based upon at least one life-cycle state of the plurality of life-cycle states of the service object; and (d) generating a quality of service security contract based upon the determination of permitted actions.

Abstract: Methods, compositions and kits for determining the developmental potential of one or more embryos are provided. These methods, compositions and kits find use in identifying embryos in vitro that are most useful in treating infertility in humans.

Abstract: Methods, compositions and kits for determining the developmental potential of one or more embryos are provided. These methods, compositions and kits find use in identifying embryos in vitro that are most useful in treating infertility in humans.